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Objective: The purpose of this study was to grow “artificial blood vessels” for autologous transplantation as arterial
interposition grafts in a large animal model (dog).
Method and results: Tubing up to 250 mm long, either bare or wrapped in biodegradable polyglycolic acid (Dexon) or
nonbiodegradable polypropylene (Prolene) mesh, was inserted in the peritoneal or pleural cavity of dogs, using minimally
invasive techniques, and tethered at one end to the wall with a loose suture. After 3 weeks the tubes and their tissue
capsules were harvested, and the inert tubing was discarded. The wall of living tissue was uniformly 1-1.5 mm thick
throughout its length, and consisted of multiple layers of myofibroblasts and matrix overlaid with a single layer of
mesothelium. The myofibroblasts stained for -smooth muscle actin, vimentin, and desmin. The bursting strength of
tissue tubes with no biodegradable mesh scaffolds was in excess of 2500 mm Hg, and the suture holding strength was
11.5 N, both similar to that in dog carotid and femoral arteries. Eleven tissue tubes were transplanted as interposition
grafts into the femoral artery of the same dog in which they were grown, and were harvested after 3 to 6.5 months. Eight
remained patent during this time. At harvest, their lumens were lined with endothelium-like cells, and wall cells stained
for -actin, smooth muscle myosin, desmin and smoothelin; there was also a thick “adventitia” containing vasa vasorum.
Conclusion: Peritoneal and pleural cavities of large animals can function as bioreactors to grow myofibroblast tubes for use
as autologous vascular grafts. (J Vasc Surg 2004;39:859-67.)For more than three decades the saphenous vein has
served as the principal conduit for autologous grafting.
However, 30% of patients who require arterial bypass pro-
cedures do not have saphenous veins suitable for use,
because of previous harvest for bypass surgery, varicose
degeneration, or inadequate diameter or length. Even suc-
cessful saphenous vein grafts are prone to development of
intimal hyperplasia and accelerated atherosclerosis.1 Thus
there is increasing use of arterial conduits for vascular
grafts,2 but these can be difficult to harvest, easily damaged,
demanding to anastomose, and easily compromised by
spasm. In peripheral vascular bypass, prosthetic polymer con-
duits are often used, but patency is less than optimal. There
have been various attempts to improve patency by surface
modification and endothelial cell seeding; however, the clini-
cal results are controversial and mostly disappointing.3,4
In view of the various shortfalls in the currently avail-
able grafts, there is a need to develop an autologous bypass
From Centre for Research in Vascular Biologya and Department of Anatomy
and Developmental Biology,b School of Biomedical Sciences, University
of Queensland, Brisbane, and Mayo Clinic,c Rochester.
Supported by grants from the National Health and Medical Research
Council of Australia (J.H.C., G.R.C.), and a CardioVascularLipid grant
from Pfizer Australia (W.L.C.).
Competition of interest: Drs Julie H. Campbell and Gordon R. Campbell
are holders of two patents relative to the work in this article: “Implant
Material,” granted in Australia and the United States, publication date
Mar 2, 2000 (WO 0010620), priority date Aug 21, 1998; and “Biore-
actors,” Australian Patent Application No. 2002950557.
Reprint requests: Julie H. Campbell, PhD, Centre for Research in Vascular
Biology, School of Biomedical Sciences, University of Queensland, Bris-
bane QLD 4072, Australia (e-mail: julie.campbell@uq.edu.au).
0741-5214/$30.00
Copyright © 2004 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2003.03.003conduit that closely resembles the native artery, not only in
its dimensions but also in its cellular constituents, physio-
logic responsiveness, mechanical properties, and anti-
thrombotic and relaxing factors released at the cellular
level. Certain characteristics are deemed important and
desirable in the ideal vascular graft.5,6 It must be durable
and maintain structural integrity, the lumen must remain
patent, and there must be uniformity throughout the graft
and across the anastomosis lines, implying absence of sig-
nificant mural thrombus, intimal hyperplasia, or atheroma-
tous change. The ideal prosthesis must be nontoxic, non-
allergenic, without carcinogenic potential, easy to sterilize,
and resistant to infection, and must be available in different
sizes to suit a wide range of vascular reconstructions. The
implant must possess flexibility, suturability, and minimal
needle hole and interstitial bleeding, and after implantation
it must generate enough tissue reaction healing without
causing excessive fibrosis. It should have the ability to
interact with the host vasculature so that flow velocity and
volume are modulated to match the capacity and resistance
of the runoff circulation. Finally, it must present a non-
thrombogenic blood-graft interface to achieve long-term
patency.
A new concept of using the peritoneal cavity as a
bioreactor in which to grow an “artery” was proposed by us
in 1999.7 This site not only serves as a humidified, temper-
ature-controlled incubator, but also supplies the cell
source, nutrients, growth factors, and other necessary com-
ponents to create a new blood vessel. Polymer tubing was
inserted into the peritoneal cavity of rats or rabbits, and in
a few days became covered by cells of hemopoietic origin
that are stimulated to enter the peritoneal cavity in response859
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into myofibroblasts, which synthesized a collagen matrix,
forming a capsule of living tissue covered by a single layer of
mesothelium on the outer surface. The living tubes of tissue
were successfully transplanted as carotid artery or aortic
interposition grafts into the same animal in which they were
grown, and it was suggested that these nonthrombogenic
tubes of tissue, grown in the peritoneal cavity of the host,
may be developed further as vascular grafts.
As a prelude to clinical testing, long-term studies in a
large animal model are necessary. This article describes
studies in the dog in which minimally invasive techniques
were used for implantation and harvest of different types of
tubing in the peritoneal and pleural cavities, then mechan-
ical testing of the conduits and their patency as vascular
grafts.
MATERIAL AND METHODS
Animal surgery. Fifteen nonpregnant female mongrel
dogs weighing between 20 and 40 kg, obtained from the
Logan Dog Pound (Brisbane, Australia) were used, under
the guidelines of and following ethical approval from the
University of Queensland Animal Ethics Committee. Dr
Julie H. Campbell was involved in the study design, had full
access to all of the study data, and takes complete respon-
sibility for the integrity of the data and the accuracy of the
data analysis and interpretation, and for writing the manu-
script and submitting it for publication.
Eleven dogs underwent implantation of tubing into the
peritoneal cavity. Premedication was acepromazine (0.25
mL/kg intramuscularly), followed by thiopentone (Pento-
thal; 15-17 mg/kg intravenously), endotracheal intubation
and maintenance of anaesthesia with halothane at 1% to 2%
in 0.5 to 1 L/min of oxygen flow. A stat dose of antibiotic
(procaine penicillin, 2-mL intramuscular injection) was
given at induction, as well as analgesia with flunixin meglu-
mine (0.25 mL/kg intramuscularly). To insert the tubing a
three-port laparoscopic technique was used, consisting of a
10-mm camera port in the midline of the epigastrium and
two other working ports placed laterally. Tubes were first
sutured at one end with 3/0 polypropylene (Prolene), and
a loop was tied. They were then inserted into the peritoneal
cavity (up to four pieces per animal) and sutured to the
ventral abdominal wall with 3/0 polypropylene. The inci-
sions were closed in layers with 2/0 polyglactin 910 (Vic-
ryl) deep and 4/0 polyglyconate (Maxon) subcuticular
stitches.
Four dogs were subjected to thoracoscopic implanta-
tion and harvesting using the pleural cavity, with open
insertion technique of the ports used to avoid injury to the
lung and heart. Carbon dioxide was insufflated through this
port into the pleural cavity under 8 to 10 mm Hg pressure
to partially collapse the lung on the side operated on. The
templates were anchored into the inner surface of the chest
wall with thoracoscopic sutures (3/0 Prolene). The
wounds were sutured closed with 2/0 Vicryl and 4/0
Maxon when the lung was fully inflated.Tubing inserts. A total of 58 pieces of tubing were
inserted, 44 in the peritoneal cavity and 14 in the pleural
cavity. Their length ranged from 80 to 250 mm, and
diameter from 3 to 4.5 mm. They were of the following
composition (Table): polyethylene (Dural Plastics & Engi-
neering, Auburn, NSW, Australia), Tygon (a polyvinyl-
chloride-based material with plasticizer; Norton Perfor-
mance Plastics, Akron, Ohio), C-flex (styrene-ethylene-
butylene modified block co-polymer with silicone oil; Cole
Palmer Instrument Co, Vernon Hills, Ill), silicone (Selby
Biolab, Mulgrave, Vic, Australia); latex polymer (A. A.
Rubber Service, Roseville, NSW, Australia); C-flex covered
with a sleeve of biodegradable polyglycolic acid sheeting
(Synthecon, Houston, Tex), polyethylene covered with
nonbiodegradable Prolene mesh (knitted filaments of ex-
truded polypropylene; Ethicon/Johnson & Johnson, Pis-
cataway, NJ), and polyethylene covered with biodegrad-
able polyglycolic acid mesh (Dexon; Sherwood Medical, St
Louis, Mo).
Tissue harvest and transplantation. Three weeks af-
ter the implantation procedure the tubular templates cov-
ered with a capsule of living tissue were located in the
peritoneal or pleural cavities and harvested with the same
minimally invasive techniques. The tubular templates were
easily slipped out of the tubes of tissue and discarded, and
the tubes of tissue were placed in a balanced salt solution at
4°C. The femoral artery was clamped proximally and dis-
tally, and the vessel was transected obliquely. Twenty mil-
liliters of heparinized saline solution was flushed proximally
and distally to prevent intravascular thrombosis during the
procedure. A 5-cm to 7-cm length of tissue tube was
prepared, and an oblique end-to-end anastomosis formed
with continuous 6/0 Prolene. Graft pulse and femoral
arterial pulse distal to the anastomosis confirmed the pa-
tency of the graft. Thereafter graft patency was monitored
weekly with clinical examination, Doppler ultrasound scan-
ning (noninvasive), or angiography. For antithrombotic
Summary of tubes implanted into peritoneal or pleural
cavities of dogs
Tubing implant*
No.
implanted
No. with
capsule
No.
grafted†N %
Polyethylene 14 7 50 5
Tygon 5 0 0 0
C-flex 10 3 33 1
Silicone 4 1 25 0
Latex 6 2 33 0
PGA sheet 2 2 100 0
Prolene mesh 9 9 100 1
Dexon mesh 8 8 100 4
PGA, Polyglycolic acid.
*Length, 80-250 mm; diameter, 3-4.5 mm.
†Number used as interposition grafts in femoral artery of same dog in which
they were grown.
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every second day.
Mechanical properties. To measure burst strength of
the tissue tubes and carotid or femoral artery controls,
silicone tubing was used to channel pressurized air through
a three-way tap to a pressure transducer at one end and the
vessel to be tested at the other end. The vessel and the
surrounding tubing were filled with methylene blue dis-
solved in isotonic saline solution (0.9%). This vessel was
then submerged in a beaker of clear isotonic saline solution
at room temperature. The signal produced by the trans-
ducer was wired into a laptop computer, and data were
collected with the Picolog software program. Incremental
(50 mm Hg) pressure increases were then introduced. The
burst strength of the test vessel was to be indicated by
leakage of methylene blue saline solution through the
vessel wall into the beaker.
The Instron universal testing machine was used to
assess the suture holding strength of the myofibroblast
tube. The load cell was a PST20 (Precision Transducers,
New Zealand) with a dynamic range of195 N. Segments
of tissue measuring 5 to 7 cm were transected in the middle,
and an end-to-end anastomosis was fashioned with contin-
uous 6/0 Prolene. The completed anastomosis was secured
in the testing cell of the machine, which was then set to a
ramp distance of 10 cm over 2 seconds. The Instron was
activated, and the force (in newtons) required to disrupt
the anastomosis was recorded wiht the Microsoft Excel
(Redmond, Wash) software program. The same experi-
ment was repeated with dog carotid and femoral arteries as
controls.
Histologic and immunofluorescence studies. Tissue
for histologic analysis was fixed in 10% buffered formalin
and paraffin-embedded, and sections were stained with
toluidine blue. For immunofluorescence studies sections of
fresh frozen tissue were stained with the following antibod-
ies: anti--SM actin (mouse immunoglobulin [Ig] G2a;
1A4), anti-SM-MHC (mouse IgG1; hSM-V), anti-calpo-
nin (mouse IgG2a; hCP), anti-vimentin (mouse IgG1; V9;
all from Sigma (St Louis, Mo); anti–smooth muscle myosin
isoform, SM-2 (mouse IgG1; Yamasa Corp, Japan); anti-
smoothelin (gift from Dr G van Eys, Maastricht, The
Netherlands); and CD45 and CD34 (Serotec, UK). The
secondary antibody was fluorescein isothiocyanate–conju-
gated anti-mouse IgG (Silenus Laboratories, Australia).
Biotinylated Ulex europaeus lectin was obtained from
Sigma, and streptavidin (Alexa) was obtained from Molec-
ular Probes (Eugene, Ore). Omission of primary antibodies
and staining with an irrelevant mouse immunoglobulin
served as negative controls. Labeled tissue sections were
examined under a confocal microscope (MRC 1024; Bio-
Rad, Hercules, Calif).
Transmission and scanning electron microscopy.
Arterial grafts and arteries were perfusion fixed at 100 mm
Hg in a solution of 2% paraformaldehyde and 1.25% glu-
taraldehyde in 0.067 mol/L cacodylate buffer for 10 min-
utes. For transmission electron microscopy this was fol-lowed by en bloc staining with 5% aqueous uranyl acetate
and embedding in Epon or Araldite; then thin sections
were stained and examined under a JEOL 1010 micro-
scope. For scanning electron microscopy the specimens
were put through a critical point dryer, then mounted on
copper disks and sputter-coated with gold particles before
viewing the luminal surface under a JEOL 6300
microscope.
Statistical analysis. All statistical analyses were per-
formed with the statistical software package SIGMASTAT
(Jandel Scientific).
RESULTS
Tissue tube formation in peritoneal and pleural
cavities. Different types of polymer tubing implanted into
the body cavities evoked different responses. Tygon pro-
duced no tissue formation; C-flex, silicone, and latex were
low responders, with 25% to 33% tissue encapsulation.
Polyethylene had a 50% response, and a thick tissue capsule
grew over the entire length of tubing (Table; Fig 1).
C-flex tubes covered with a tube of polyglycolic acid
sheeting induced a very florid inflammatory response and
formation of a thick granulation tube; however, surround-
ing bowel loops were densely adherent, with hyperemic
reaction, and this tissue was discarded. In contrast, when
tubing of any type was encapsulated by mesh, either non-
biodegradable Prolene or biodegradable Dexon, a thick
capsule of tissue grew around the entire length of tubing in
100% of cases. If the tubing was implanted high in the
peritoneal cavity, sometimes omentum partially wrapped
around the tubing. However, when it was anchored low in
the abdomen or when partial omentectomy was performed
or 200 mL of peritoneal dialysate was added, this was less of
a problem. There were few adhesions in the pleural cavity,
and no difference in degree of tubing encapsulation be-
tween the peritoneal and pleural cavities.
At histologic analysis there was no discernable differ-
ence between the capsules grown in the two body cavities,
on the different types of tubing, and with or without a mesh
scaffold. The capsules were homogeneous, and consisted of
densely packed spindle-shaped cells arranged transversely
around the lumen (Fig 2, A). These stained intensely for
-smooth muscle actin (Fig 2, B) and vimentin, and to a
lesser extent for desmin (Fig 2, C), but were negative for
both smooth muscle myosin and smoothelin. About 1 cell
in 10 still stained for CD45 (Fig 2, D), similar to that seen
in 2-week capsules around boiled blood clots in the perito-
neal cavity of mice,8 where nearly 100% of cells stained early
in capsule formation. A small number of cells were positive
for CD34 (not shown). Between the cells was deposited
considerable matrix, which stained intensely for collagen,
but there was little elastin.
When the bursting strength of the tubes of tissue that
had been grown without a mesh scaffold was measured,
the luminal pressure exceeded 2500 mm Hg, without any
of the vessels bursting or leaking and with no aneurysm
swelling (n 3). Indeed, between 2330 and 2890 mm Hg
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occurred when the bursting strength of similar lengths of
dog carotid or femoral arteries was measured (n  6).
When the tubes of tissue or femoral or carotid arteries (n
8) were transected transversely and resutured, the suture
holding strength was highest for the newly grown tissue
(11.5 N), followed by carotid arteries (8.4 N) and femoral
arteries (7.1 N). It was thus considered that tubes of living
tissue grown in the dog peritoneal or pleural cavities over 3
weeks from cells floating in the constituent fluid were
sufficiently strong to be sutured as interposition grafts into
the femoral artery of the same dog in whose body cavity
they had grown.
Transplanted grafts. To date, 11 myofibroblast tubes
have been transplanted as interposition grafts in the dog
femoral artery. Six of these were without mesh, whereas one
had nondegradable Prolene mesh and four had biodegrad-
able Dexon mesh (Table). Three of the Dexon mesh–
containing grafts and five without mesh remained patent
until the animals were killed, between 3 and 6.5 months, as
observed on Doppler scans and direct observation after
killing and dissection (Fig 3, A). In grafts that had biode-
gradable Dexon scaffolds, all traces had disappeared by 3
months. No vessels had aneurysm dilatations, and the wall
thickness was even throughout the graft. There was little or
no intimal thickening in the region of the anastomoses (Fig
3, B), and in the three cases in which the graft was not
patent (one each Dexon, Prolene, no mesh) the cause was
organized thrombus rather than intimal hyperplasia.
At histologic analysis the grafts were about the same
thickness as when they were harvested from the peritoneal
or pleural cavity: 1.1  0.4 mm for those without mesh,
and 1.6  0.4mm for those with mesh. However, while
previously the cells were evenly dispersed throughout the
full thickness of the wall, now there was clear demarcation
between a dense cellular inner region (“media”) versus
more sparsely cellular outer region (“adventitia”). This was
Fig 1. A, Capsule of avascular tissue that has grown arou
external diameter, placed in the peritoneal cavity of a do
B, Capsule of tissue about 20 cm long, grown in the dog
removed.evident at 3 months, and did not change over time. At
immunofluorescence studies the cells of the “media”
stained strongly for smooth muscle myosin (Fig 4, A),
whereas as pre-implant tissue they had been very weak or
negative. Also stained were many small blood vessels (vasa
vasorum) in the outer part of the “adventitia.” The “me-
dia” also reacted strongly for -smooth muscle actin, and
vimentin, desmin, and smoothelin (Fig 4, B-D), as did the
vasa vasorum. The cells in the “media” were usually elon-
gated spindle shaped (Fig 5, A), and separated from each
other by collagen bundles with interspersed elastin and
other extracellular matrix components. Ultrastructurally
their appearance was of normal smooth muscle cells with
variable cytoplasmic components. Some cells contained a
cytoplasm predominantly filled with myofilaments (Fig 5,
B), and others contained synthetic organelles such as mito-
chondria and rough endoplasmic reticulum.
Lining the lumen of the graft was a flattened layer of
cells (Fig 6, A) that stained strongly for vimentin (Fig 4, B)
but not for -smooth muscle actin, smooth muscle myosin,
desmin, or smoothelin. The cells also stained strongly with
an antibody for Ulex lectin, indicating their endothelial-like
nature (Fig 6, B), which was confirmed with transmission
electron microscopy. At scanning electron microscopy
these cells had a smooth luminal surface (Fig 6, C) similar
to the endothelial lining of native vessels.
Graft tissue (no mesh) from two dogs (4 months and
6.5 months) was tested for reactivity in an organ bath
(101 mol/L potassium chloride, 105 mol/L acetylcho-
line, 105 mol/L 5-hydroxytryptamine, 104 mol/L
phenylephrine), but none was found despite positive re-
sponses from segments of adjacent femoral artery from the
same animals. The reason for this is not known, particularly
inasmuch as graft tissue in rats was vasoreactive,7 but it may
be related to the highly fibrous adventitia that developed in
the dog graft.
iece of polyethylene tubing 80 mm long, with 4.75-mm
3 weeks. Thickness of the wall of tissue is about 1 mm.
oneal cavity for 3 weeks, with inner polyethylene tubingnd a p
g for
perit
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We previously showed that insertion of 10-mm to
20-mm lengths of polymer tubing into the peritoneal cavity
of rats and rabbits resulted in formation of a capsule of
nonvascularized living tissue around the free-floating im-
plant within 2 weeks.7 The tissue capsules consisted of
several layers of myofibroblasts and the collagen-rich matrix
they had produced, plus an outer lining of confluent me-
sothelial cells. At harvest, the living tissue was removed
from the tubing and everted so that the mesothelium now
lined the lumen. The tubes of tissue were then sewn as
autologous interposition grafts into the carotid artery (rab-
bit) or abdominal aorta (rat), where they remained patent
for at least 4 months, with the myofibroblasts in the wall
becoming more like smooth muscle, both ultrastructurally
and functionally.
Fig 2. Sections of a capsule of tissue grown around a len
for 3 weeks. A, Stained with hematoxylin-eosin. B, Immu
desmin. D, Immunostained for CD45.The present study extends these results in several im-
portant ways. First, it shows that in larger animals (dog)
capsules of tissue can be grown up to 250 mm long within
3 weeks with minimally invasive (laparoscopic) techniques.
In addition, the tubing is loosely tethered at one end to the
ventral surface of the peritoneal wall to enable the encap-
sulated tubing to be readily located and laparoscopically
retrieved. Since four pieces of tubing of this length (as
loops) can be inserted and anchored, potentially up to 1 m
of vascular graft material can be grown at any one time.
Second, tubes of living tissue can be grown in the pleural
cavity and the peritoneal cavity. This may be important if
they are to be used as coronary artery bypass grafts, because
they are already located on-site. Third, under full sterile
conditions uncoated polymer tubing induces capsule for-
mation only 50% of the time or less, whereas tubing coated
f polyethylene tubing in the peritoneal cavity of the dog
ained for -smooth muscle actin. C, Immunostained forgth o
nost
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gradable Prolene produces 100% success. Fourth, tubes of
living tissue (without a scaffold) have a bursting strength in
excess of 2500 mm Hg, which is comparable with dog
femoral and carotid arteries. Fifth, the tissue tubes do not
have to be everted before grafting, so that the mesothelium
lines the lumen, so long as the animals are given antithrom-
botic therapy after surgery. Finally, with or without a
scaffold mesh, the graft differentiates into a structure re-
sembling the native artery, with an “endothelial” lining, a
“media” of smooth muscle–like cells, and an “adventitia”
complete with vasa vasorum. These studies build on the
pioneering work of Sparks9,10 and others,11,12 who grew
tubes of tissue subcutaneously around mandrils and suc-
cessfully used them as arterial grafts in dogs and human
beings, with long patency.
Our results raise several interesting questions. Why
does a free-floating structure such as a length of tubing
become coated by cells that are morphologically macro-
Fig 3. A, Central region of a tube of tissue that had gro
after it had been grafted into the femoral artery in the
anastomosis. Arrow, suture.
Fig 4. Immunostaining of a tube of tissue grown in the
femoral artery of the same dog for 4 months. A, Smoothphages within peritoneal or pleural fluid? What stimulates
capsule formation? What stimulates these cells to differen-
tiate into myofibroblasts within the peritoneal or pleural
cavities, then into smooth muscle–like cells once trans-
planted to a high-pressure arterial site?
Currently we have little information abut any of these
points. It has been known for several decades that introduc-
tion of any small foreign body (eg, plastic disk, boiled liver
or blood clot, agar, gelatin, egg white, filter membranes)
into the peritoneal cavity initiates an inflammatory response
and capsule formation,13-15 and assumed that this is the
body’s way of sealing off the foreign implant from self. The
inflammatory response leads to the production of various
cytokines in the peritoneal cavity, and an (as yet) unknown
combination appears to induce the cells of hemopoietic
origin to differentiate into myofibroblasts. Potential candi-
dates are transforming growth factor1, platelet-derived
growth factor B, endothelin-1, granulocyte-macrophage
colony-stimulating factor, and interleukins 4 and 13, which
the peritoneal cavity of a dog for 3 weeks, 6.5 months
dog. B, Same graft, but at the region of the proximal
oneal cavity of a dog for 3 weeks, then grafted into the
cle myosin. B, Vimentin. C, Desmin. D, Smoothelin.wn in
sameperit
mus
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tiation into a viable blood vessel is at least partially due to
wall stretching from pulsatile flow, as shown by Niklason et
al,22 who used cultured vascular smooth muscle cells
seeded onto a biodegradable mesh in a bioreactor in vitro.
We showed previously that myofibroblasts as tubular struc-
tures fresh from the peritoneal cavity increased their vol-
ume fraction of myofilaments within 24 hours of cyclic
stretching 5% to 10% above resting length at 50 cpm.23 In
other studies,24-29 monocytes and macrophages (or other
cells of hemopoietic origin) differentiated into smooth
muscle–like cells within the neointima that forms as a result
of transplant atherosclerosis or after severe arterial injury.
Unlike our earlier study,7 the tissue tubes were not
everted before grafting into severed native artery. There-
fore, what is the source of the “endothelial” lining observed
when the animals are killed up to 6.5 months later? There
are at least four potential sources of this “endothelium.”
The mostly likely is pannus ingrowth from the adjacent
natural artery. However, circulating CD34, Kit, Flk-
1, and Tie-2 endothelial progenitors30 cannot be ex-
cluded, and these cells have recently been shown to cover
Fig 5. Elongated spindle-shaped “smooth muscle cell” from a
tube of tissue grown in the peritoneal cavity of a dog for 3 weeks,
then grafted into the femoral artery of the same dog for 6.5
months. A, Basal lamina and collagen bundles orientated in differ-
ent directions surround the cell. Bar  1 m. B, Higher magnifi-
cation of a smooth muscle cell from the same graft as in A
demonstrates the presence of an extensive cytoplasmic network of
myofilaments with associated dark bodies. A lipid droplet, mito-
chondria, and rough endoplasmic reticulum are also observed. A
thick floccular basal lamina and collagen fibers surround the cell.
Bar  200 nm.decellularized sheep grafts, producing fully functioning
grafts in vivo.31 It is also possible that mesothelial cells on
the outside of the grafted tube of tissue migrate through
the wall to line the interface between tissue and flowing
blood, or that the cells of the myofibroblast tube, originally
derived from hemopoietic cells, retain sufficient plasticity to
differentiate into endothelial-like cells,32 because human
monocytes cultured in the presence of angiogenic growth
factors acquire the properties of endothelial cells.33 Also, it
Fig 6. Cells lining the lumen of a tube of tissue grown in the
peritoneal cavity of a dog for 3 weeks, then grafted into the femoral
artery of the same dog for 4 months. A, Stained with toluidine
blue. B, Immunostained for Ulex lectin. C, Scanning electron
microscopic view.
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cells can arise from the same progenitor.34 Further differ-
entiation of the CD45 cells of the capsule into smooth
muscle–like cells expressing first -smooth muscle actin and
desmin, then later smooth muscle myosin and smoothelin,
is itself remarkable. However, many forms of transdifferen-
tiation have been reported, including endothelial-mesen-
chymal transdifferentiation of mature vascular endothelium
into smooth muscle cells.35 It is unlikely that these cells
within the “media” are derived from the native vessel from
pannus ingrowth, because the thickness of the cell-rich
region of the original graft did not change significantly, and
at all times when animals were killed (3-6.5 months) only a
small and well-defined intimal thickening was observed at
the region of anastomosis, and there was no variation in
immunostaining of the “media” throughout its length.
The source of the “neoadventitia” is also not clear. It is
this region where the graft is greatly thickened, and the
outer region contains a well-established vasa vasorum.
Most likely it is derived from surrounding connective tis-
sue, but again it cannot yet be excluded that the source of at
least some of the cells is the original tube of myofibroblasts,
which have been directed to transdifferentiate by signals in
the local environment.
Irrespective of the cellular source of any of the layers of
the artificial blood vessel, it is clear that a tube of living
tissue can be produced in the peritoneal (and pleural)
cavities of at least four animal species (mouse, rat, rabbit,
and now dog) for autologous transplantation as an inter-
position graft that remains patent for many months. It
remains to be tested whether similar tubes of living tissue
can be grown in the body cavities of human beings, partic-
ularly those with conditions such as hypercholesterolemia,
diabetes, or uremia, in need of a vascular graft in the form of
a coronary artery bypass graft, a below-knee artery replace-
ment, or an arteriovenous access fistula for hemodialysis.
We are encouraged that smooth muscle progenitors have
recently been isolated from human blood.36
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In: “Disease of the aorta” (Valentine RJ [book review]. J Vasc Surg 2004;39:490)
The title and authors of the reviewed book are incorrectly identified, as well as the year of publication and the number
of pages. The review is actually a review of the book “A practical textbook of congenital and acquired diseases of the
aorta, second edition,” by Domingo Liotta, Denton A. Cooley, Miguel del Rio, Hazim J. Safi, Christian Cabrol, Si
M. Pham, et al; Buenos Aires, Argentina 2003; School of Medicine, University of MoRo´n; 682 pages; $225.
In: “Percutaneous treatment of symptomatic central venous stenosis angioplasty” (Sprouse LR II, Lesar CJ,
Meier GH, Parent FN, Demasi RJ, Gayle RG, et al. J Vasc Surg 2004;39:578-82)
The word “angioplasty” was incorrectly added to the title during the production process. The correct title of this
article is “Percutaneous treatment of symptomatic central venous stenosis.”
